Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L23a pseudogene 33 (RPL23AP33) is a **processed pseudogene** of the ribosomal protein L23a gene, meaning it is a non-coding RNA sequence in the human genome that resembles the functional RPL23A gene but does not encode a functional protein product[1][2][6]. Pseudogenes such as RPL23AP33 can function as long non-coding RNAs (lncRNAs) and have been implicated in gene regulation, but they do not serve as classical therapeutic targets like receptors, enzymes, or transporters[1][5]. Studies on closely related pseudogenes (e.g., RPL23AP53) suggest that their expression levels may be associated with cellular proliferation and prognosis in cancer (such as melanoma), and thus could potentially serve as novel biomarkers, but there is no evidence indicating that RPL23AP33 itself is druggable or interacts with any therapeutic compounds[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L23a pseudogene 33 (RPL23AP33).